Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commercialisation Deal on Haemostatix Products

27 Sep 2017 07:00

RNS Number : 8982R
Ergomed plc
27 September 2017
 

PRESS RELEASE

 

 

Ergomed Signs First Commercialisation Deal for Haemostatix Products

 

- Boryung Pharmaceutical Co.Ltd licenses PeproStat™ and ReadyFlow™ for commercialisation in South Korea

 

- Ergomed to receive an upfront and future milestone payments as well as double-digit share of product sales

 

- Deal driven by British innovation in the treatment of surgical bleeding with multi-million dollar potential

 

London, UK / Seoul, Republic of Korea - 27 September 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a specialised pharmaceutical services and drug development company, and Boryung Pharmaceutical Co. Ltd (Korea Stock Exchange, KRX: 003850) ("Boryung"), a pharmaceutical business with R&D, manufacturing and marketing capabilities, are pleased to announce an agreement to commercialise Ergomed's haemostat products PeproStat™ and ReadyFlow™ in South Korea.

 

Under the terms of the collaboration, Ergomed will receive an upfront and a series of milestone payments as well as a double-digit share of all future product sales in this territory. Today's agreement is the first in a series of anticipated deals that will support global sales of the products, which were obtained through Ergomed's acquisition of Haemostatix in 2016.

 

Dr. Miroslav Reljanovic, Executive Vice Chairman of Ergomed, said: "We are very pleased to sign our first commercialisation deal on the Haemostatix products. This partnership underlines the broad, global interest in novel, innovative haemostats, and endorses the Haemostatix platform, confirming its potential to generate significant future value to Ergomed and its shareholders. Korea is a rapidly growing market for haemostats and Boryung is an ideal partner with their marketing capability and experience with innovative drugs."

PeproStat is an innovative haemostat for the control of bleeding during surgical procedures. The product is based on a peptide that binds to fibrinogen in blood to promote localized clotting in a wound. Current therapies are based on the enzyme thrombin which require multiple preparation steps and are manufactured from blood donations with the related risks of infection and a complex supply chain. In contrast PeproStat is synthetic, fast acting and ready-to-use. PeproStat has completed recruitment in a Phase IIb study in five European countries with data expected in Q4 2017, and it is anticipated that the product will reach the market in 2020 in Europe and 2021 in Korea. ReadyFlow is a flowable formulation that is particularly suited to less accessible bleeds. The product is in pre-clinical development. ReadyFlow was awarded first prize in the UK's Royal Society of Chemistry Emerging Technology Competition.

 

The global haemostat market is forecast to grow to $2.76billion by 2020[i]. Ergomed estimates that PeproStat and ReadyFlow together have peak sales potential of more than $500 million[ii].

 

Mr. Tae-Hong Choi, Chief Executive Officer of Boryung Pharm said: "Boryung Pharm is one of the largest pharmaceutical companies in South Korea with a leading position in the market. We look forward to working with Ergomed and to making the potential value of the Haemostatix platform available soon in South Korea." He added, "PeproStat and ReadyFlow will offer surgeons a valuable new tool as the products work quickly and effectively, do not require preparation time, and can be used in a range of surgical settings. We have the strong ambition of a rapid market penetration with these innovative products, and are proud to strengthen our competence in surgical procedures."

 

ENDS

 

 

Enquiries:

 

Ergomed plc

Tel: +44 (0) 1483 503205

Miroslav Reljanovic (Executive Vice Chairman)

Andrew Mackie (Chief Business Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

N+1 Singer

Tel: +44 (0) 20 7496 3000

Alex Price (Joint Broker)

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

ergomed@consilium-comms.com

MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

 

About Ergomed

 

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

 

About Boryung Pharmaceutical Co., Ltd.,

 

Boryung Pharmaceutical Co., Ltd is a leading pharmaceutical company in Korea fully integrated from R&D through manufacturing, marketing and sales with an established presence in Korea. The company has focused on the development and commercialization of new pharmaceutical products. Its main therapeutic categories are oncology, cardiovascular, anti-infective and respiratory system.

Additional information can be found at www.boryung.co.kr

 


[i] Hemostats Market by Product Type (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), and Geography (Americas, Europe, APAC, MEA) - Global Forecast to 2020. MarketsandMarkets, February 2016.

[ii] Company estimate

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRDMGZLNVZGNZM
Date   Source Headline
14th Nov 20237:00 amRNSCancellation - Ergomed plc
13th Nov 20233:30 pmRNSForm 8.3 - ERGO LN
13th Nov 20233:20 pmRNSForm 8.3 - Ergomed plc
13th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Ergomed Plc
13th Nov 202310:37 amRNSScheme of Arrangement becomes Effective
13th Nov 202310:24 amRNSForm 8.5 (EPT/RI) - Ergomed Plc
13th Nov 20237:30 amRNSSuspension - Ergomed plc
10th Nov 20233:47 pmRNSHolding(s) in Company
10th Nov 20233:30 pmRNSForm 8.3 - ERGO LN
10th Nov 20233:30 pmGNWForm 8.3 - Ergomed plc
10th Nov 20233:29 pmRNSForm 8.3 - Ergomed plc
10th Nov 20233:20 pmRNSForm 8.3 - Ergomed plc
10th Nov 20233:15 pmPRNForm 8.3 - Ergomed Plc
10th Nov 20233:05 pmRNSHolding(s) in Company
10th Nov 202312:05 pmGNWForm 8.3 - Ergomed PLC
10th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Ergomed Plc
10th Nov 202310:50 amGNWMan Group PLC : Form 8.3 - Ergomed plc
10th Nov 202310:45 amRNSForm 8.3 - Ergomed plc
9th Nov 20233:30 pmGNWForm 8.3 - Ergomed plc
9th Nov 20233:20 pmRNSForm 8.3 - Ergomed plc
9th Nov 20232:27 pmRNSIssue of Equity and Rule 2.9 Announcement
9th Nov 20232:16 pmRNSCourt Sanction of the Scheme of Arrangement
9th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Ergomed Plc
8th Nov 20236:00 pmRNSErgomed
8th Nov 20233:20 pmRNSForm 8.3 - Ergomed plc
8th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Ergomed Plc
8th Nov 20238:12 amRNSForm 8.5 (EPT/NON-RI) Ergomed Plc
7th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Ergomed Plc
6th Nov 20233:30 pmGNWForm 8.3 - Ergomed plc
6th Nov 20233:20 pmRNSForm 8.3 - Ergomed plc
6th Nov 20232:04 pmGNWForm 8.3 - Ergomed Plc
6th Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Ergomed Plc
6th Nov 202311:50 amRNSForm 8.3 - Ergomed plc
6th Nov 20238:34 amRNSForm 8.5 (EPT/NON-RI) Ergomed Plc
3rd Nov 20233:30 pmGNWForm 8.3 - Ergomed plc
3rd Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Ergomed Plc
3rd Nov 20239:33 amGNWMan Group PLC : Form 8.3 - Ergomed plc
2nd Nov 20233:30 pmGNWForm 8.3 - Ergomed plc
2nd Nov 20233:21 pmRNSStatement re Publication of Finance Documentation
2nd Nov 202312:48 pmGNWForm 8.3 - Ergomed Plc
2nd Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Ergomed Plc
2nd Nov 202311:45 amRNSForm 8.3 - Ergomed plc
2nd Nov 20237:59 amRNSForm 8.5 (EPT/NON-RI) Ergomed Plc
1st Nov 20233:20 pmRNSForm 8.3 - Ergomed plc
1st Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Ergomed Plc
1st Nov 202312:00 pmRNSForm 8.5 (EPT/RI) - Ergomed Plc
1st Nov 202311:25 amRNSForm 8.3 - Ergomed plc
1st Nov 20238:50 amRNSForm 8.5 (EPT/NON-RI) Ergomed Plc
1st Nov 20237:00 amRNSIssue of Equity and Rule 2.9 Announcement
31st Oct 20235:09 pmGNWForm 8.3 - Ergomed plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.